This site is intended only for healthcare professionals resident in the Republic of Ireland
Menu
Close
Menu
Close
Click here for CIBINQO Prescribing Information. Adverse event reporting information can be found at the bottom of the page.
Laboratory abnormalities observed across clinical studies in moderate-to-severe AD patients treated with CIBINQO 200 mg or CIBINQO 100 mg¹
Thrombocytopenia
Lymphopenia
Discover the efficacy of CIBINQO
Consistent safety profile with patients with moderate-to-severe AD studied across JADE clinical trials
Prescribing information
Please see the CIBINQO Summary of Product Characteristics for more information.
Discover the efficacy of CIBINQO
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.
Legal Category: S1A
Further information is available upon request
Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
Adverse events should also be reported to Pfizer Medical Information on 1800 633 363
Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.
This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie
This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.
Copyright © 2023 Pfizer Limited. All rights reserved.
The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.
I confirm that I am a healthcare professional resident in the Republic of Ireland.*
I accept and agree to the terms of use.*
If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.
PP-UNP-IRL-0176. January 2023